These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35471066)

  • 1. The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma.
    Williams DM
    J Manag Care Spec Pharm; 2022 May; 28(5):581-583. PubMed ID: 35471066
    [No Abstract]   [Full Text] [Related]  

  • 2. Is tezepelumab the ubiquitous biologic for severe asthma?
    Beasley R; Chang AB
    Lancet Respir Med; 2023 May; 11(5):393-395. PubMed ID: 36702145
    [No Abstract]   [Full Text] [Related]  

  • 3. Tezepelumab (Tezspire) for severe asthma.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):25-26. PubMed ID: 35171894
    [No Abstract]   [Full Text] [Related]  

  • 4. In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.
    Taleb AA; Badgett RG
    Ann Intern Med; 2021 Oct; 174(10):JC115. PubMed ID: 34606305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma.
    Corren J; Wechsler ME; Chupp G; Roseti SL; Hellqvist Å; Martin N; Llanos JP; Ambrose CS; Colice G
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):943-945.e2. PubMed ID: 36375743
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
    Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
    J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
    Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
    N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma.
    Lipworth B; Chan R
    Am J Respir Crit Care Med; 2023 Jul; 208(2):211. PubMed ID: 37279364
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma.
    Corren J; Chen S; Callan L; Gil EG
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):211-214. PubMed ID: 32474159
    [No Abstract]   [Full Text] [Related]  

  • 10. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study.
    Shinkai M; Ebisawa M; Fukushima Y; Takeuchi S; Okada H; Tokiyo T; Hayashi N; Takikawa M; Colice G; Almqvist G
    J Asthma; 2023 Mar; 60(3):616-624. PubMed ID: 35707873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal antibodies for severe asthma (review)].
    Solèr M
    Ther Umsch; 2019 Nov; 76(6):317-321. PubMed ID: 31762416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making.
    Desai M; Oppenheimer J
    Ann Allergy Asthma Immunol; 2019 Oct; 123(4):331-332. PubMed ID: 31351166
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical efficacy of tezepelumab in pre-selected non-type 2 asthma patients.
    Chin-See-Chong TCT; Valk JPMJV; Layhadi JAJ; Shamji MHM; Kappen JHJ
    Allergy; 2024 Oct; 79(10):2867-2870. PubMed ID: 39034850
    [No Abstract]   [Full Text] [Related]  

  • 14. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
    Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date.
    Dorey-Stein ZL; Shenoy KV
    Drug Des Devel Ther; 2021; 15():331-338. PubMed ID: 33536746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe refractory eosinophilic asthma].
    Jäger-Becker D
    MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
    [No Abstract]   [Full Text] [Related]  

  • 17. Biological treatment is approved for severe eosinophilic asthma.
    Mayor S
    BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
    [No Abstract]   [Full Text] [Related]  

  • 18. How do we interpret the data supporting the use of omalizumab for severe asthma?
    Lavietes MH
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):335-6. PubMed ID: 25256024
    [No Abstract]   [Full Text] [Related]  

  • 19. A New Monoclonal Antibody Treats Severe Asthma.
    Aschenbrenner DS
    Am J Nurs; 2016 Jul; 116(7):24-5. PubMed ID: 27336986
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.